[120 Pages Report] The global stem cell therapy market is a highly competitive market. This market is estimated to reach USD 145.76 million by 2021 from USD 86.5 million in 2016, at a CAGR of 11.0% during the forecast period. Growth in the stem cell therapy market is fuelled by the increasing number of scientific research activities focused on utilizing the therapeutic potency of stem cells for disease treatment, and the introduction of stem cell line banking. The development of induced pluripotent stem cell (iPSC) lines has also contributed to the growth of this market. The growing socio-ethical issues associated with embryonic stem cells have led to the increased adoption of iPSCs as alternatives.

By therapeutic applications, the musculoskeletal disorders segment is expected to be the largest segment of the market

On the basis of therapeutic applications, the stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, surgery, and other therapeutic applications. The musculoskeletal disorders segment dominates the global stem cell therapy market in 2016, owing to factors such as larger number of commercialized stem cell therapy products for the treatment of musculoskeletal disorders and the increasing prevalence of musculoskeletal disorders (coupled with the growth in geriatric population).

On the basis of cell sources, the adipose tissue-derived MSCs segment dominates the global stem cell therapy market in 2016

On the basis of cell source, the stem cell therapy market is segmented into adipose tissue-derived mesenchymal stem cells (MSCs), bone marrow-derived MSCs, cord blood/embryonic stem cells (SCs), and other stem cell lines. The adipose tissue-derived MSCs segment dominates the global stem cell therapy market in 2016. The growth of this segment is attributed to the growing demand for easy and accessible stem cell source and wide range of therapeutic applications offered by adipose tissue-derived stem cells. However, the bone marrow-derived MSCs segment is projected to witness the highest CAGR during the forecast period. Growth in this segment is driven by the increasing number of products launched based on bone-marrow derived MSCs, easy availability of cell source for harvesting cells, and less complications associated with the processing of bone marrow-derived MSCs.

North America dominated the market in 2016

North America (comprising the US and Canada) accounts for the largest share of the global stem cell therapy market in 2016, followed by Asia-Pacific. Factors such as rising public awareness related to the therapeutic potency of stem cells in disease therapy, growing number of clinical trials that aim to evaluate the therapeutic potential of stem cell-based products, increasing public-private funding & research grants for developing safe and effective stem cell therapy products, and growing patient base for target diseases (such as cancer, leukemia, neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases) are driving the growth of the North American stem cell therapy market.

Market Dynamics

Stem cell therapies possess significant potential in the treatment of various diseases and injuries. With several public and private organizations playing an active role in funding and encouraging stem cell-based research programs, the global stem cell therapy market is expected to grow at a significant pace during next decade. The stem cell therapy market comprises a range of stem cell-based products which are utilized for the treatment of various diseases such as cancer, acute graft-vs-host disease (GvHD), tissue regeneration, as well as wounds and injuries

Stem cell therapy has been acclaimed to bring significant and revolutionary changes in the field of disease management strategies and patient care. These products offer effective treatment of conditions such as cancer, aGVHD, and vascular diseases. In recent years, stem cell therapy has been considered as a promising candidate in the field of regenerative medicine for the replacement or regeneration of damaged tissues. Moreover, there is growing awareness in the industry related to the therapeutic potency of stem cell for effective disease management. This is supported by the rising number of clinical trials and successful research studies that aim to validate the therapeutic potential of stem cell-based products. Few of the recent clinical trials are mentioned below:

Xuzhou Medical University (China) initiated an interventional study in 2016 (last updated in October 2016). This study is aimed at the therapeutic evaluation of adipose-derived stem cells or fat cells for facial rejuvenation.

The Affiliated Hospital of Academy of Military Medical Sciences (China) initiated an interventional phase 1 and phase 2 study in collaboration with Ivy Institute of Stem Cells Co. Ltd (China) in 2015 (last updated in March 2016). The study is aimed at testing the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treatment of patients with chronic heart ischemia cohort.

Celal Bayar University (Turkey) initiated an interventional phase 1 study in collaboration with the Scientific and Technological Research Council (Turkey) and Ac�badem Labcell (Turkey) in 2016 (last updated in July 2016). The study is aimed at determining the safety and efficacy of mesenchymal stem cells derived from autologous adipose tissue for the treatment of chronic autoimmune urticaria.

Moreover, there are 5,888 active NIH-registered stem cell-based clinical trials being conducted worldwide. These clinical trials are expected to augment the consumer adoption and physician preference for stem cell therapies across major markets. This is expected to drive the demand growth for stem cell therapy products worldwide during the forecast period

Restraint: Socio-ethical issues related to the use of ESCs in disease treatment

Stem cell therapy makes use of living cells for the development of products used in a wide range of therapeutic applications. It is widely used for developing regenerative medicine for tissue and organ regeneration to cater to the growing demand for organ transplantation across the globe. However, the use of stem cells inside the human body is associated with several biosafety concerns; also, some religions do not accept defiling of the human body due to religious principles.

A number of ethical issues are associated with the use of stem cells in as these cells are derived by destructing the human embryo. The human embryo is viewed as potential life, and destroying it is considered to unethical even if it can save a human life. Such concerns related to the use of embryonic stem cells for developing stem cell therapy is a major factor restraining the market growth across the globe.

Scope of the Report

Report Metric Details Market Size Available for Years 2014-2021 Base Year Considered 2015 Forecast Period 2016-2021 Forecast Units Value (USD) Segments Covered Type, therapeutic application, cell source, and region Geographies Covered North America, Europe, APAC, and the RoW Companies Covered Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (US), RTI Surgical, Inc. (US), and AlloSource (US)

This report categorizes the stem cell therapy market into the following segments and subsegments:

Global Stem Cell Therapy Market, by Type

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications

Autologous Market, By Application Wounds and Injuries Cardiovascular Diseases Gastrointestinal Diseases Other Applications



Global Stem Cell Therapy Market, by Therapeutic Application

Musculoskeletal Disorders

Wounds and Injuries

Cardiovascular Diseases

Surgeries

Gastrointestinal Diseases

Other Applications

Global Stem Cell Therapy Market, By Cell Source

Adipose Tissue-Derived Mesenchymal Stem Cells

Bone Marrow-Derived Mesenchymal Stem Cells

Cord Blood/Embryonic Stem Cells

Other Cell Sources

Global Stem Cell Therapy Market, by Region

North America

Europe

Asia Pacific

Rest of the World (RoW)

Key Market Players

As of 2015, the global stem cell therapy market was dominated by Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (US), RTI Surgical, Inc. (US), and AlloSource (US) among others.

Osiris Therapeutics, Inc. (US) held the leadership position in the global stem cell therapy market in 2015. The company�s product portfolio includes allogeneic stem cell-based products for musculoskeletal disorders (such as Bio4) and wounds and injuries application (such as Grafix, Stravix, and TruSkin). The company has a strong geographic presence in North American market. It primarily focuses on product development and commercialization to increase its revenue and strengthen its market position. The market has witnessed several product launches by Osiris Therapeutics in the last three years, such as Stravix (November 2015), TruSkin (November 2015), and Grafix (July 2014). This expanded the company�s stem cell-based product portfolio and strengthened its revenue base in stem cell therapy market.

MEDIPOST Co., Ltd. (South Korea) held the second position in the global stem cell therapy market in 2015. The company has a strong foothold in the stem cell therapy market. The company offers stem cell therapy product for musculoskeletal disorder (such as CARTISTEM). Furthermore, the company has diverse product pipeline in developmental phase. The company focuses on expanding its presence in the global stem cell therapy market by opting expansion strategy. In line with this, the company partnered with JingYuan Bio Ltd. (China), established a joint venture�OrLife Bio. (December 2014), entered into an agreement with Alkem Laboratories Ltd. (India) for commercialization of CARTISTEM (December 2013), and established MEDIPOST Hong Kong (its corporate office in Hong Kong) (January 2013). Additionally, the company focuses on organic growth strategy such as product development and commercialization to expand its product portfolio and strengthen its revenue base in stem cell therapy market. In line with this strategy the company received the Orphan Drug designation for its product PNUEMOSTEM (December 2013) and launched its new stem cell therapy product for musculoskeletal disorder namely, CARTISTEM (January 2012).

Recent Developments:

In July 2016, JCR Pharmaceuticals signed a pharmaceutical development agreement with Medipal Holdings Corporation (Japan). JCR Pharmaceuticals received R&D funding for two drug programs from Medipal Holdings Corporation, and in return, Medipal Holdings Corporation received a fixed percentage of sales in Japan after the products were launched. This agreement helped JCR Pharmaceuticals to expand its distribution facilities in the Asian stem cell therapy market

In April 2016, JCR Pharmaceuticals completed the construction of its new Clinical Trial Material Manufacturing Center (CTMC) and Cell Processing Center (CPC) at its research institute located in Kobe, Japan. The CPC facility is designed to manufacture raw materials required for preclinical and clinical trials of cell therapy and regenerative medicinal products.

In November 2015, JCR Pharmaceuticals established JCR International SA, its new subsidiary in Fribourg, Switzerland. This helped the company to expand its presence in Europe.

In November 2015, Osiris Therapeutics launched Stravix, a cryopreserved human placental tissue designed for soft tissue repair specifically in surgical procedures. Stravix comprises amniotic and connective layers of the umbilical tissue along with viable mesenchymal stem cells and growth factors.

Key questions addressed in the report:

What are the growth opportunities related to stem cell therapy market across major regions in the future?

Emerging countries have immense opportunities for the growth and adoption of stem cell therapy. Will this scenario continue in the next five years?

What are the market shares of allogenic and autologous stem cell therapy in the overall market?

What are the new trends and advancements in the allogenic and autologous stem cell therapy segment?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst